Relationship between Mucormycosis and Coronavirus: A Review
DOI:
https://doi.org/10.46243/jst.2021.v6.i04.pp01-03Keywords:
Coronavirus infection, Mucormycosis,, fungal infection, immune-boosting, pulmonary (lung, cutaneous mucormycosisAbstract
The human immune system is predominantly damaged and weakened by the coronavirus. As a result, even after recovering from one infection, the patient's immune system is insufficient to protect him from other ailments such as bacterial and fungal infections. One of the negative effects of Covid-19 infection is mucormycosis. Mucormycosis is a fungus infection caused by fungi belonging to the Mucorales family. These fungi can be found in soil, compost piles, decomposing wood, and decaying organic waste such as leaves, among other places. Every day, everyone is exposed to millions of fungus spores. Safe people, on the other hand, have a strong immune system to keep them safe. Many fungal infections spread quickly after Covid-19 infection due to the patient's weakened immune system. Mucormycosis is a common fungus that affects people who have had Covid-19 or who have had it after having Covid-19. Mucormycosis is an extremely rare disease. Persons with weakened immune systems are more susceptible to infection, although it can even strike seemingly healthy people in rare cases. Following Covid19 infestations, there are a variety of immune-boosting foods to pick from, each of which help in building immunity and battling a number of virus infections. Protein-rich diets, omega-3 fatty acid-rich meals, high antioxidant-rich meals, and the most important pharma-therapeutic foods like garlic, turmeric, and green tea should be consumed after Covid-19 infections.
References
Chakrabarti, A., Denning, D. W., Ferguson, B. J., Ponikau, J., Buzina, W., Kita, H., & Radotra, B. D. (2009). Fungal rhinosinusitis: a categorization and definitional schema addressing current controversies. The Laryngoscope, 119(9), 1809-1818
Charles Patrick David, MD, PhD Medical Editor: Mary D. Nettleman, MD, MS, MACP Medically Reviewed on 5/10/2021
Ferguson, B. J. (2000). Definitions of fungal rhinosinusitis. Otolaryngologic clinics of north America, 33(2), 227-235
Fernandez, J. F., Maselli, D. J., Simpson, T., & Restrepo, M. I. (2013). Pulmonary mucormycosis: what is the best strategy for therapy?. Respiratory care, 58(5), e60-e63
Gleissner, B., Schilling, A., Anagnostopolous, I., Siehl, I., & Thiel, E. (2004). Improved outcome of zygomycosis in patients with hematological diseases?. Leukemia & lymphoma, 45(7), 1351-1360
Hibbett, D. S., Binder, M., Bischoff, J. F., Blackwell, M., Cannon, P. F., Eriksson, O. E., & Zhang, N. (2007). A higher-level phylogenetic classification of the Fungi. Mycological research, 111(5), 509-547
Ibrahim, A. S., Edwards, J. E. J., & Filler, S. G. (2003). Zygomycosis. 241–251. Clinical mycology. Oxford University Press, New York, NY
Karimi‐Galougahi, M., Arastou, S., & Haseli, S. (2021, March). Fulminant mucormycosis complicating coronavirus disease 2019 (COVID‐19). In International forum of allergy & rhinology
Lewis, R. E., & Kontoyiannis, D. P. (2013). Epidemiology and treatment of mucormycosis. Future microbiology, 8(9), 1163-1175
Marr, K. A., Carter, R. A., Crippa, F., Wald, A., & Corey, L. (2002). Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clinical Infectious Diseases, 34(7), 909-917
Parashar A, Gupta SK, Kumar A. Anthocyanin concentration of KANDARI Pomegranate fruits during different cold storage conditions. ACI, XXXIV C. 2008; 3:529-536
Park SY, Seetharaman R, Ko MJ, Kim TH, Yoon MK, Kwak JH, Lee SJ, Bae YS, Choi YW. Ethyl linoleate from garlic attenuates lipopolysaccharide-induced pro-inflammatory cytokine production by inducing heme oxygenase-1 in RAW264. 7 cells. International Immunopharmacology. 2014; 19(2):253-61
Petrikkos, G., Skiada, A., Lortholary, O., Roilides, E., Walsh, T. J., & Kontoyiannis, D. P. (2012). Epidemiology and clinical manifestations of mucormycosis. Clinical Infectious Diseases, 54(suppl_1), S23-S34
Revannavar, S. M., Supriya, P. S., Samaga, L., & Vineeth, V. K. (2021). COVID-19 triggering mucormycosis in a susceptible patient: a new phenomenon in the developing world?. BMJ Case Reports CP, 14(4), e241663
Ribes, J. A., Vanover-Sams, C. L., & Baker, D. J. (2000). Zygomycetes in human disease. Clinical microbiology reviews, 13(2), 236- 301
Spellberg, B., Edwards, J., & Ibrahim, A. (2005). Novel perspectives on mucormycosis: pathophysiology, presentation, and management. Clinical microbiology reviews, 18(3), 556-569
Sugar, A. M. (1992). Mucormycosis. Clinical infectious diseases, 14(Supplement_1), S126-S129
Tabarsi, P., Khalili, N., Pourabdollah, M., Sharifynia, S., Naeini, A. S., Ghorbani, J.,... & Askari, E. (2021). COVID-19 associated rhinosinusitis mucormycosis due to Rhizopus oryzae: A rare but potentially fatal infection occurring after treatment with corticosteroids
Therakathu, J., Prabhu, S., Irodi, A., Sudhakar, S. V., Yadav, V. K., & Rupa, V. (2018). Imaging features of rhinocerebral mucormycosis: A study of 43 patients. The Egyptian Journal of Radiology and Nuclear Medicine, 49(2), 447-452
Vairaktaris, E., Moschos, M. M., Vassiliou, S., Baltatzis, S., Kalimeras, E., Avgoustidis, D., & Moschos, M. N. (2009). Orbital cellulitis, orbital subperiosteal and intraorbital abscess. Report of three cases and review of the literature. Journal of Cranio-maxillofacial surgery, 37(3), 132-136. 3 | Page
